EVUSHELD: payments to doctors
Payments that named EVUSHELD as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $250K
- Providers
- 3,287
- Transactions
- 4,589
- Average per transaction
- $54
The per-transaction average — $54 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,287 providers the average total is $76, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| AstraZeneca | $227,056 | 90.9% |
| Astrazeneca UK Limited | $22,586 | 9.0% |
| Astrazeneca AB | $78 | 0.0% |